Syneron Bio
Updated: May 08, 2026
CEO - Xiao Zhang
Country: China | Funding: $250M (+)
Founded: 2022
Website: https://www.syneronbio.com
Syneron leverages AI through its proprietary Synova macrocyclic peptide platform. The company describes macrocyclic peptides as a “goldilocks” drug class due to their ability to bridge the gap between small molecules and biologics, enabling the targeting of traditionally difficult disease pathways. Using this technology Syneron develops a pipeline across multiple indications in oncology, autoimmune, metabolic and rare disease programs.
Founded: 2022
Website: https://www.syneronbio.com
Syneron leverages AI through its proprietary Synova macrocyclic peptide platform. The company describes macrocyclic peptides as a “goldilocks” drug class due to their ability to bridge the gap between small molecules and biologics, enabling the targeting of traditionally difficult disease pathways. Using this technology Syneron develops a pipeline across multiple indications in oncology, autoimmune, metabolic and rare disease programs.
